Posted by Michael Wonder on 13 Nov 2016
U.S. FDA approves Gilead’s Vemlidy (tenofovir alafenamide fumarate) for the treatment of chronic hepatitis B virus infection
10 November 2016 - Vemlidy is a once-daily treatment that demonstrated similar efficacy with improved renal and bone laboratory safety parameters compared to Viread.
Gilead Sciences today announced that the U.S. FDA has approved Vemlidy (tenofovir alafenamide fumarate or TAF) 25 mg, a once-daily treatment for adults with chronic hepatitis B virus infection with compensated liver disease.
Vemlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below for important safety information.
